PubRank

Markus Guba

Author PubWeight™ 50.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007 14.87
2 Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int 2012 2.17
3 Loss of liver transplant surgeons into alternate career paths. Transpl Int 2014 2.04
4 Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 2010 1.59
5 Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011 1.44
6 Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004 1.40
7 Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007 1.38
8 Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008 1.35
9 Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004 1.28
10 Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004 1.19
11 GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis 2003 1.19
12 The intrinsic renal compartment syndrome: new perspectives in kidney transplantation. Transplantation 2010 1.10
13 Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012 1.06
14 Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004 1.02
15 Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004 1.01
16 Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol 2005 0.99
17 Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther 2007 0.99
18 The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007 0.97
19 Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int 2013 0.94
20 Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) 2010 0.90
21 Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 2007 0.89
22 Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis 2005 0.88
23 Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005 0.88
24 Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 2007 0.86
25 Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res 2002 0.85
26 Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis. Transplantation 2012 0.84
27 Neutrophil gelatinase-associated lipocalin and end-stage renal disease: it is not all about the kidneys! Eur J Clin Invest 2013 0.78
28 99mTc-MAG3 scintigraphy for the longitudinal follow-up of kidney function in a mouse model of renal ischemia-reperfusion injury. EJNMMI Res 2012 0.78
29 mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005 0.78
30 Reperfusion of liver graft during transplantation: techniques used in transplant centres within Eurotransplant and meta-analysis of the literature. Transpl Int 2013 0.78
31 Decompression of inflammatory edema along with endothelial cell therapy expedites regeneration after renal ischemia-reperfusion injury. Cell Transplant 2012 0.77
32 Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition. Ther Drug Monit 2013 0.76
33 Impact of surgical training and surgeon's experience on early outcome in kidney transplantation. Langenbecks Arch Surg 2013 0.76
34 Effect of Apheresis for ABO and HLA Desensitization on Anti-Measles Antibody Titers in Renal Transplantation. J Transplant 2011 0.75
35 Extended pancreas donor program - the EXPAND study rationale and study protocol. Transplant Res 2013 0.75
36 Use of drug-eluting balloon coronary intervention prior to living donor kidney transplantation. BMC Cardiovasc Disord 2014 0.75
37 Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2008 0.75
38 BK virus-associated nephropathy: neutrophil gelatinase-associated lipocalin as a new diagnostic tool? Clin Transplant 2013 0.75
39 [Multimodal treatment of colorectal liver metastases]. MMW Fortschr Med 2015 0.75
40 Model for end-stage liver disease score in the first 3 weeks after liver transplantation as a predictor for long-term outcome. Eur J Gastroenterol Hepatol 2016 0.75
41 [Chances and risks of live donor liver transplantation]. MMW Fortschr Med 2014 0.75
42 Differential significance of early surgical complications for acute and long-term recurrence-free survival following surgical resection of hepatocellular carcinoma: do comorbidities play a role? Eur J Gastroenterol Hepatol 2017 0.75